Genelux Corporation (GNLX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Genelux Corporation
Address
2625 Townsgate Road
Westlake Village, CA 91361
United States of America (the)
Phone
858 483 0024
Website
Sector
Healthcare
Industry
Biotechnology
Employees
24
First IPO Date
January 26, 2023
Key Executives
| Name | Title | Pay | Year Born |
| Thomas Zindrick | Chairman, Chief Executive Officer & President | 784,159 | 1960 |
| Yong Yu | Chief Scientific Officer | 242,615 | 1972 |
| Joseph Cappello | Chief Technical Officer | 470,834 | 1957 |
| Matthew Pulisic | Chief Financial Officer and Principal Financial & Accounting Officer | 489,558 | 1984 |
| Eric Groen | General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development | 0 | 1971 |
| Ralph Smalling | Vice President & Head of Regulatory Affairs | 0 | 1955 |
| Jason Litten | Chief Medical Officer | 0 | 1974 |
Description
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
